Xin Lang Cai Jing·2026-02-26 10:21Core Insights - Sangamo's significant revenue growth in 2025 is attributed to a collaboration with Pfizer, resulting in a reported revenue of 4.199 billion yuan, a 251.81% increase year-on-year, and a net profit of 2.939 billion yuan, reflecting a 317.09% increase [1][9] - The company received a non-refundable upfront payment of 1.25 billion USD from Pfizer for the development rights of the PD-1/VEGF bispecific antibody SSGJ-707, which is a key driver of its financial performance [4][12] - The competitive landscape for PD-1/VEGF bispecific antibodies is intensifying, with multiple players entering the market, prompting Sangamo to focus on core pipeline innovations and differentiated development strategies [2][10] Financial Performance - In 2025, Sangamo reported total revenue of 4.199 billion yuan, a 251.81% increase from the previous year [1][9] - The net profit attributable to shareholders reached 2.939 billion yuan, marking a 317.09% increase year-on-year [1][9] - The company's non-GAAP net profit, excluding certain income and expenses, was 2.805 billion yuan, reflecting a staggering 1041.01% increase [1][9] Strategic Partnerships - Sangamo's collaboration with Pfizer includes a 1.25 billion USD upfront payment and potential milestone payments up to 4.8 billion USD based on development and sales achievements [4][12] - The agreement grants Pfizer exclusive rights to develop, manufacture, and commercialize SSGJ-707 globally, excluding mainland China [4][12] Market Competition - The PD-1/VEGF bispecific antibody market is becoming increasingly competitive, with several companies, including Kintor Pharma and BMS/BioNTech, advancing their own candidates [2][10] - As of now, there are 17 PD-(L)1/VEGF bispecific antibodies in clinical trials globally, indicating a crowded field [5][13] Research and Development Pipeline - Sangamo has a total of 22 projects in its research pipeline, with 7 in Phase III clinical trials, including candidates targeting autoimmune diseases [7][15] - The company has recently received approval for its anti-IL-17A monoclonal antibody, which is aimed at treating moderate to severe plaque psoriasis [16][15] Industry Trends - The IL-17 antibody market is also highly competitive, with multiple products already approved and many more in clinical development [8][17] - The success of PD-1/VEGF bispecific antibodies is closely watched, with recent clinical trial results impacting market confidence [6][14]